Clinical trials recruiting in Biała Podlaska, Poland

Phase breakdown

Conditions recruiting in Biała Podlaska, Poland

Recruiting trials in Biała Podlaska, Poland

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
  NCT06979375 · Phase: Phase 2 · Ages: 40 Years to 84 Years · Sex: All (male and female)
• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
  NCT06435429 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
  NCT06750094 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  NCT06662786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
  NCT06926868 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
  NCT07743463 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
  NCT05696626 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
  NCT06677060 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female)
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
  NCT06380751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
  NCT06307652 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Biała Podlaska, Poland?

12 recruiting trials have at least one study site in Biała Podlaska, Poland.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.